Back to search

The University of Edinburgh

Trends and outcomes associated with the potential overuse of antenatal corticosteroids

Abstract

dc:description.abstract

Preterm birth (before 37 weeks’ gestation) is the leading global cause of death in children under 5 years of age. The administration of antenatal corticosteroids (ACS) before imminent preterm birth is an important therapy to reduce neonatal mortality and morbidity in babies. The use of ACS has expanded to include women from 22 to 38 weeks’ gestation, even when the risk of impending delivery is relatively low. However, gaps exist in knowledge surrounding the long-term effects and optimal timing of ACS. Potential overuse of ACS is a concern, as up to half of the babies exposed to ACS are subsequently born at term (≥ 37 weeks’ gestation), by which stage neonatal benefits are minimal. Additionally, the administration of ACS late preterm (34-36 weeks’ gestation), or before Caesarean section at early term (37 until 39 weeks’ gestation), remains controversial, as evidence is insufficient to determine whether potential risks outweigh benefits at these gestations. Fetal overexposure to glucocorticoids may influence early life programming of disease. A robust evaluation of the safety of ACS administration is paramount, particularly regarding ACS exposure in babies born at term. Term-born babies may be exposed to ACS via suboptimally timed ACS (given before anticipated preterm birth, but the woman does not deliver until term), or ACS administered at late preterm or term gestations. This thesis aimed to investigate potential overuse of ACS, and to evaluate associations with short- and long-term outcomes, using routinely collected maternity, neonatal and childhood data. To investigate the incidence of potential overuse of ACS, and its variation over time and location, I collaborated with a data analyst to create an international cohort (the “Co-OPT ACS cohort”) which amalgamated population-based observational individual patient data on the use of ACS. We cleaned and harmonised data from Finland, Iceland, Israel, Nova Scotia (Canada) and Scotland to create a database of 2,276,156 babies born between 22 to 45 weeks’ gestation, from 1990 to 2019, containing information on ACS use and a range of maternal, neonatal and childhood outcomes. Our descriptive analysis of the cohort found that the overall ACS exposure rate was 3.6% (n=72,490) of babies and had increased over time. Of all ACS-exposed babies in the cohort, 26.8% (n= 19,410) were born at term, the majority of whom had been exposed to ACS earlier in pregnancy but had not delivered preterm. In a subset of the Scottish population, the administration of ACS from 34 weeks’ gestation onwards was commonplace (46.8% (n=1320) of all ACS-exposed babies born in Aberdeen). I used the Co-OPT ACS cohort to evaluate the association of ACS exposure with early child neurodevelopment in a subset of 285,637 children born in Scotland at 28-41 weeks’ gestation, between 2011 and 2017. In this population-based cohort study, records of categorical and continuous assessments of neurodevelopment, undertaken by health professionals and parents at population-wide health reviews for children aged 27-30 months, were analysed using multivariable logistic and linear regression, stratified by gestational age at birth. In children born at 28-33 weeks’ gestation, ACS exposure was associated with reduced odds of concern about early childhood neurodevelopment. In children born at 34-36, 37-38 and 39-41 weeks’ gestation, no independent associations were found between ACS exposure and neurodevelopment at 27-30 months of age. I undertook an observational cohort study of 2186 babies born in NHS Lothian (a health board in Scotland) from 2010 to 2020 to evaluate the practice of “prophylactic” ACS administration, given within seven days before planned Caesarean birth at early term, and to examine its association with neonatal and maternal outcomes. Analyses used multivariable logistic regression, and for neonatal outcomes, were stratified by gestational age at birth. Rates of prophylactic ACS use before planned Caesarean birth varied markedly over the study period; in singleton pregnancies, annual prophylactic ACS exposure rates ranged from 0 to 73.7% of babies born at 37+0 to 37+6 weeks’ gestation, and 0 to 46.8% of babies born at 38+0 to 38+6 weeks’ gestation. In singletons, prophylactic ACS exposure before planned Caesarean birth at 37+0 to 37+6 weeks’ gestation was associated with reduced odds of neonatal unit admission within 48 hours of birth for respiratory morbidity, and reduced need for immediate neonatal resuscitation; these associations were not seen in babies born at 38+0 to 38+6 weeks’ gestation. No association was found between prophylactic ACS exposure and neonatal unit admission within 48 hours of birth for neonatal hypoglycaemia in singleton babies in either gestational age group. Mothers who received prophylactic ACS before planned Caesarean birth at early term had increased odds of postnatal infection within 72 hours of birth compared to mothers who didn’t receive prophylactic ACS. No associations were found between prophylactic ACS and postnatal depression, based on validated screening questionnaires undertaken by health professionals in the community. Decisions to administer ACS can be challenging, particularly in patient subgroups where the balance of risks and benefits is unclear. To improve shared decision making surrounding the administration of ACS before early term Caesarean birth, I created a patient decision support tool in collaboration with a parental advisory board and an artist. The methods and materials involved in its creation have been outlined, and the key themes identified during this process, relevant to shared decision making in perinatal care, were considered. In summary, this thesis has examined the potential overuse of ACS in clinical practice, highlighting the high rates of ACS-exposed babies born at term and rising rates of overall ACS exposure, despite a lack of evidence to support its use across all populations. This research offers new insight into the interplay between ACS exposure, gestational age at birth and neurodevelopment in early childhood. Further studies are required to establish whether potential associations of ACS with neurodevelopment will emerge later in childhood. Prophylactic ACS administration before planned Caesarean birth of singletons at 37 until 38 weeks’ gestation was associated with reduced odds of both NNU admission with respiratory morbidity and reduced need for immediate neonatal resuscitation, although the novel finding of its potential association with maternal postpartum infection needs closer evaluation. A patient decision support tool can improve shared decision making on the use of ACS in clinical contexts where the balance of risks and benefits is unclear; parents faced with these situations value transparency and clear communication of uncertainties. This thesis underlines the need to optimise administration of ACS for those who will benefit most, while reducing potentially unnecessary treatment.

Degree

thesis:*
Grantor dc:publisher
The University of Edinburgh
Year dc:date.issued
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Frier, Emily Margaret
Advisors dc:contributor.advisor
  • Stock, Sarah
  • Reynolds, Rebecca

Subjects

dc:subject × 8

Rights

Language dc:language.iso
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Edinburgh
Base URL
era.ed.ac.uk/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Frier, Emily Margaret. Trends and outcomes associated with the potential overuse of antenatal corticosteroids. The University of Edinburgh, 2024. https://hdl.handle.net/1842/42704